
Replimune is a biotech company that aims to transform cancer treatment by pioneering the development of oncolytic immunotherapies.
Join us in revolutionizing cancer treatment by building insights and analytics capabilities. This role will be integral to the commercial organization in delivering a successful launch for Replimune's lead asset RP1 in PD-1 failed melanoma, as well as future indications.
Replimune is a biotech company that aims to transform cancer treatment by pioneering the development of oncolytic immunotherapies.